Neurocrine Biosciences Announces Webcast and Conference Call
Company to Present Results From Phase III Clinical Trial With Indiplon in 200 Subjects With Primary (Chronic) Insomnia
SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will host a Conference Call and Webcast to report on the Phase III clinical trial results with indiplon for Primary (Chronic) Insomnia. The Conference Call and Webcast will be held today, Monday, April 21, 2003 at 4:30 PM Eastern Daylight Time (EDT)/1:30 PM Pacific Daylight Time (PDT). Participants may access the live Conference Call by dialing 1-800-903-0247 (US) or 785-832-1077 (International) and using the access code of NBIX or Neurocrine. The call can also be accessed via the Webcast through the Company's website at www.neurocrine.com or through a link provided by PR Newswire at http://www.firstcallevents.com/service/ajwz379978670gf12.html .
Gary A. Lyons, President and CEO of Neurocrine Biosciences and members of the senior management team will present the results from the Phase III clinical trial with indiplon. If you are unable to attend the Webcast and would like further information on this announcement please contact Claudia Jones or Elizabeth Foster in the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600.
A replay of the call will be available approximately two hours after the call concludes and can be accessed by dialing 1-800-388-9064 (US) or 402-220-1116 (International). The call will be archived until Monday, May 5, 2003.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, autoimmunity and certain female and male health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.